MK-431 (Merck).
Merck & Co is developing MK-431, the lead from a series of dipeptidyl peptidase IV inhibitors that enhance endogenous glucagon-like peptide-1 levels, for the potential treatment of type 2 diabetes. Phase III studies were initiated in the second quarter of 2004.
Deacon
Carolyn F
CF
Department of Medical Physiology, Panum Institute, University of Copenhagen, DK-2200 Copenhagen N, Denmark. deacon@mfi.ku.dk
D000243:Adenosine Deaminase / Q000494:pharmacology / Q000627:therapeutic use*; D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D002986:Clinical Trials as Topic; D000075202:Contraindications; D018819:Dipeptidyl Peptidase 4 / Q000494:pharmacology / Q000627:therapeutic use*; D004345:Drug Industry / Q000379:methods / Q000639:trends; D006023:Glycoproteins / Q000037:antagonists & inhibitors* / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011719:Pyrazines / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*
D058892:Adenosine Deaminase Inhibitors; D006023:Glycoproteins; D007004:Hypoglycemic Agents; D011480:Protease Inhibitors; D011719:Pyrazines; D014230:Triazoles; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4; D000243:Adenosine Deaminase; D000068900:Sitagliptin Phosphate